Advance RI-CTR — From Research Support to Connected Statewide Infrastructure
Advance RI-CTR is evolving from research support toward a connected statewide infrastructure linking institutions, clinical environments, expertise and shared resources.
NYJ-CAN-BIO — Building Translational Infrastructure Around Shared Technologies
NYJ-CAN-BIO is building shared technology and translational infrastructure for NeuroHIV biomarker research across Weill Cornell Medicine and Rutgers Health.
ExTENd — Turning Distributed Research Capabilities into Accessible Infrastructure
ExTENd is developing a central platform to connect distributed technologies, expertise and infrastructure across institutions in Lower Saxony.
KIRO.NRW — Connecting AI Robotics Across Four Distributed Research Environments
With up to €100 million in planned funding, KIRO.NRW will connect four AI robotics environments across eight institutions. Its key challenge is turning distributed technologies into one functioning research infrastructure.
COVIM — Scaling Standardized Immune Profiling Across 25 Sites
COVIM is scaling standardized immune profiling across up to 25 sites. Its real infrastructure challenge lies in harmonizing workflows, quality processes and technology implementation across multiple laboratories.
Inside an NK1 Antagonist Journey: A Pharmacologist’s Perspective
“Initially, we thought NK1 receptor antagonists would be most useful for asthma, depression, or pain — but they turned out to be critical for preventing nausea and vomiting in chemotherapy and post-operative care.” — Mike Snider
MOSAIC – One Microscope to Rule Them All?
One microscope, twelve modalities: How MOSAIC redefines correlative imaging through modular design and adaptive optics.
Deep Phenotyping And AlphaFold
Marc Bickle discusses how Deep Phenotyping and AlphaFold are transforming early-stage drug discovery. Learn about cutting-edge technologies that enhance precision in oncology and neurodegenerative research, offering new insights and accelerating the development of personalized therapies through advanced AI-driven methods and high-content imaging.
Guardians of Health
Thomas Müller, a distinguished scientist with over 30 years' experience in ion channel research, talks about his journey from studying biology in Heidelberg and Glasgow to leading high-throughput screening at Bayer, where he's been at the forefront of scientific innovation. In this enlightening session, Thomas shares his remarkable journey and delves into the fascinating world of ion channels.